Obermatt
See Similar Stocks →

Flags

Financial distress

Cerus

NMQ:CERS · US1570851014
Health Care Equipment & SuppliesSmall

360

45
Profit price89
Owner Earnings Yield1
Dividend Yield1
Price/Sales42
EV / Gross Profit56
Price/Book5
Return on Capital21
Cash Return on Capital23
Return on Equity23
EBIT Margin18
Gross Profitability84
Accruals76
Owner Earnings Margin32
Sales growth85
Profit growth20
Reinvestment39
Price momentum93
Debt load26
Refinancing52
Debt Payback1
Liquidity22
Analyst ratings100
Opinion Changes50
Price Target Upside96
Market mood44
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cerus clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded1991
Employees285
Websitecerus.com
ISINUS1570851014
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsHematologyBiomedical EngineeringIndustrial AutomationManufacturingSmart Building

Description

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on the company’s proprietary technology for controlling biolog…

Analysis

Middle-of-the-road

Cerus Corporation sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is fragile. The company scores 10/20 on our value-creation score: creating some value. Analysts lean positive.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
36
2023202420252026

All-time high

50

Jan 2023

All-time low

4

Jan 2024

Average rank

29

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
42
69
69
48
Price/Earnings
100
22
22
22
Price/Book
5
13
11
14
Dividend Yield
1
1
1
1
Value (overall)
31
27
23
31

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cerus with its peers
Haemonetics
NYQ:HAE
46
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
Utah Medical Products
NSQ:UTMD
79
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Sanara MedTech
NAQ:SMTI
52
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Delcath Systems
NAQ:DCTH
34
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Kewaunee Scientific
NMQ:KEQU
79
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Solventum
NYQ:SOLV
62
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →